tiprankstipranks
Trending News
More News >
Braveheart Investment Group PLC (GB:TRUE)
LSE:TRUE
UK Market

Braveheart Investment (TRUE) AI Stock Analysis

Compare
5 Followers

Top Page

GB:TRUE

Braveheart Investment

(LSE:TRUE)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 4o)
Rating:43Neutral
Price Target:
Braveheart Investment Group faces significant financial instability, marked by declining revenues and profitability issues, despite having no debt. Technical analysis indicates a bearish trend, with the stock trading below key moving averages and being oversold. Valuation metrics are unattractive due to a negative P/E ratio and no dividend yield. However, the recent strategic investment in IQ-AI Ltd is a positive development that might enhance its market position, but overall risks remain high.

Braveheart Investment (TRUE) vs. iShares MSCI United Kingdom ETF (EWC)

Braveheart Investment Business Overview & Revenue Model

Company DescriptionBraveheart Investment Group plc is a private equity and venture capital firm specializing in seed, start-up, early stage, growth stage, expansion stage, growth capital, turnaround, restructuring, management buy-out, management buy-in, spinout, loan and mezzanine funding, and follow-on and secondary purchase stage investments in unquoted emerging companies. It also provides equity & equity-linked investments in growth, small and medium sized enterprises and B2B. The firm does not invest in any project involved in shipbuilding, coal, or steel sector; is involved in dealing in land, commodities, futures or the instruments of any holding company that are traded on a stock exchange, wholesale trade or retailing; former ECSC sectors; agriculture, aquaculture, fisheries, synthetic fibre, production; railway, road haulage, maritime and aviation transport companies; banking, insurance, money lending, debt factoring, hire purchase financing and other financial activities; leasing or letting assets on hire; providing legal or accountancy services; operating or managing hotel or nursing or residential care homes, film production, hotels, and property (although this may be considered as part of a wider transaction). It primarily invests in technology, manufacturing, food and drink, chemical, biosciences, healthcare, creative and digital industries, information and communications technology/software/telecoms/media, environmental technologies, financial and business services, sports sector, bio-medical, engineering, materials, information sciences, and computing technology sectors in the higher education sector, retail, and service industry based businesses. It also invests in debt. It typically invests in small and medium enterprises based in United Kingdom and Ireland. It prefers to invest in Yorkshire and Humber region. The firm seeks to invest between £0.010 million ($0.012 million) and £10 million ($15.71 million) in its portfolio companies but will also participate in larger syndicates where sums raised might be £5 million ($7.70 million) to £10 million ($15.41 million). It prefers to take minority stake and typically holds its investments for a period of two to five years. The firm prefers to take board seat and co-lead its investments. The firm also provides advisory services. Braveheart Investment Group plc was founded in 1997 and is based in Barnsley, United Kingdom with additional offices in Europe and Asia.
How the Company Makes MoneyBraveheart Investment makes money primarily through management fees and performance fees associated with its asset management services. These fees are charged to clients based on the assets under management (AUM) and the performance of the investment portfolio. Additionally, the company generates revenue from its venture capital activities by investing in high-growth potential startups and earning returns on these investments. Financial advisory services also contribute to the company's earnings through consultancy fees. Strategic partnerships with financial institutions and co-investment opportunities further enhance Braveheart Investment's revenue streams by expanding its reach and leveraging shared resources.

Braveheart Investment Financial Statement Overview

Summary
Income Statement
35
Negative
Balance Sheet
60
Neutral
Cash Flow
40
Negative
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Braveheart Investment Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.80
Price Trends
50DMA
2.09
Negative
100DMA
2.13
Negative
200DMA
2.74
Negative
Market Momentum
MACD
-0.09
Positive
RSI
14.81
Positive
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TRUE, the sentiment is Negative. The current price of 1.8 is below the 20-day moving average (MA) of 1.98, below the 50-day MA of 2.09, and below the 200-day MA of 2.74, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 14.81 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TRUE.

Braveheart Investment Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
* Financial Sector Average
Performance Comparison

Braveheart Investment Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Braveheart Investment Group Expands Stake in IQ-AI Ltd
Positive
Mar 18, 2025

Braveheart Investment Group plc has increased its stake in IQ-AI Ltd by subscribing to 7,000,000 new shares in a recent placing, raising its holding to 29.35% of IQ-AI’s enlarged share capital. This strategic investment is seen as a significant addition to Braveheart’s portfolio, potentially enhancing its market position and offering stakeholders increased value through IQ-AI’s innovative imaging platforms and therapeutics.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025